TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female, aged \>=18 years.~* Subject must have histologic diagnosis of breast carcinoma.~* Subject must have documented measurable metastatic breast cancer by appropriate radiologic imaging.~* Subject must have previous anthracyclin-based adjuvant regimen and disease-free status for at least one year following the completion of adjuvant therapy.~* Subject must have ECOG performance status 0, 1, or 2.~* Subject must have life expectancy \> 6 months~* Subject must have left ventricular ejection fraction \>=55% as determined by MUGA scan.~* Subject must have normal organ function, except if abnormal due to tumor involvement:~  * Adequate bone marrow function (platelets \>=100 X 10\^9/L, hemoglobin \>=90 g/L, Neutrophils \>=1.5 X 10\^9/L)~ * Adequate renal function (serum creatinine \< 2 X the upper limit of normal (ULN)~ * Adequate liver function (bilirubin \< 2 times ULN, AST or ALT \< 2 times ULN in the absence of liver metastasis, AST or ALT \< 5 times ULN in the presence of liver metastasis.~* Women of childbearing potential must be using adequate contraception and have a negative pregnancy test at the time of enrollment.~* Subject must be able to understand and give informed consent.~Exclusion Criteria:~* Age \> 75 years old.~* Subject who is pregnant or breastfeeding or is unwilling to use adequate contraception.~* Subject who has had a previous chemotherapy for metastatic disease.~* Subject who has history of cardiac disease, with New York Heart Association Class II or greater with congestive heart failure.~* Subject who has clinically significant hepatic disease in regard to Hepatitis B, Hepatitis C, cirrhosis, or other liver diseases unrelated to the underlying metastatic breast cancer.~* Subject who has uncontrolled bacterial, viral, or fungal infection.~* Subject who exhibits confusion or disorientation.~* Subject with any condition which would prevent adequate follow-up.~* Subject who has received radiotherapy in the last 4 weeks.~* Subject with any other active primary tumor under treatment, except basal cell carcinoma of the skin, or carcinoma in situ of the cervix.~* Subject who has brain metastasis.~* Subject who is not able to give informed consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): Caelyx 35 mg/m2 and Cyclophosphamide 600 mg/m2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Dose of 1% Tropicamide and 10% Phenylephrine for Pupillary Dilation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* aged between 20 and 80 years old~* dark iris~* require binocular indirect ophthalmoscopy for complete ocular examination~* signed written consent forms~Exclusion Criteria:~* history of ocular trauma~* history of intraocular surgery~* history of laser treatment~* previous eye drop instillation that may affect pupillary dilation~* ocular diseases that may affect pupil size such as Horner's syndrome, Adies' pupil, glaucoma and uveitis~* history of diabetes mellitus, severe hypertension and cardiovascular diseases

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): single dose vs three doses of 1%tropicamide and 10%phenylephrine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible subjects must be receiving adequate thrice weekly maintenance hemodialysis with a dialysate calcium concentration ≥ 2.5 mEq/L for at least 3 months prior to screening laboratory assessments~* Subjects must have SHPT as defined by one central laboratory screening predialysis serum PTH value \> 500 pg/mL, measured on separate days within 2 weeks prior to randomization~* Subjects must have one serum cCa value ≥ 8.3 mg/dL obtained before dialysis within 2 weeks of the date of randomization~* Subjects receiving calcium supplements must have no more than a maximum dose change of 50% within 2 weeks before screening laboratory assessments are obtained, and the dose must remain unchanged through randomization~Exclusion Criteria:~* Eligible subjects cannot have received cinacalcet during the 3 months preceding the first screening laboratory assessment~* Other criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Cinacalcet (Type: ACTIVE_COMPARATOR): Participants were randomized to receive oral cinacalcet once daily and placebo intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks. The starting dose of cinacalcet was 30 mg daily and could have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining corrected calcium (cCa) ≥ 8.3 mg/dL.
- Etelcalcetide (Type: EXPERIMENTAL): Participants were randomized to receive etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW, and daily oral doses of placebo tablets for 26 weeks. The starting dose of etelcalcetide was 5 mg, and could have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining cCa ≥ 8.3 mg/dL.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* 18 to 79 years of age, inclusive~* Chronic Kidney Disease (eGFR \<60 mL/min), not yet on dialysis~* Hemoglobin (Hgb) ≤ 10.5 g/dL~* Transferring saturation ≥ 20%~* Ferritin ≥ 50 ng/mL~Key Exclusion Criteria:~* Body mass index \>42~* Red blood cell transfusion within 12 weeks~* Androgen therapy within the previous 21 days prior to study dosing~* Therapy with any approved or experimental erythropoiesis stimulating agent (ESA) within the 11 weeks prior to the Screening visit~* Participants meeting the criteria of ESA resistance within the previous 4 months~* Individual doses of intravenous iron of greater than 250 mg within the past 21 days~* Aspartate aminotransferase or alanine aminotransferase \>1.8x upper limit of normal (ULN)~* Alkaline phosphatase \>2x ULN~* Total bilirubin \>1.5x ULN~* Uncontrolled hypertension~* New York Heart Association Class III or IV congestive heart failure~* Myocardial infarction, acute coronary syndrome, or stroke within 6 months prior to dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- AKB-6548 240 mg (Type: EXPERIMENTAL): None
- AKB-6548 370 mg (Type: EXPERIMENTAL): None
- AKB-6548 500 mg (Type: EXPERIMENTAL): None
- AKB-6548 630 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gentamicin Versus Clindamycin Versus Normal Saline Lavage in Axilla

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of breast neoplasms~* plans to undergo an elective ALND of Berg's levels I and II due to axillary metastasis determined preoperatively by core biopsy or evidence of metastasis in the SLNB in the intraoperative or in the differed analysis.~Exclusion Criteria:~* allergy to any of the antibiotic drugs used~* chronic renal failure due to possible toxicity of gentamicin~* patients undergoing a modified radical mastectomy.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Irrigation with Gentamicin solution (Type: EXPERIMENTAL): The surgical bed is irrigated with a gentamicin solution
- Irrigation with Clindamycin solution (Type: EXPERIMENTAL): The surgical bed is irrigated with a clindamycin solution
- Irrigation with Normal saline (Type: PLACEBO_COMPARATOR): The surgical bed is irrigated with normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Injectable Platelet-Rich Fibrin (i-PRF) in Initial Treatment of Chronic Periodontitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A minimum of 6 teeth per quadrant;~  * A minimum of 2 teeth in each quadrant with a probing depth (PD) ≥5 mm;~ * Bleeding on probing (BOP) had to be at ≥40% tooth sites;~ * No involvement of furcation;~ * Good general health.~Exclusion Criteria:~* Periodontal therapy within last 12 months;~  * Having surgical therapy;~ * Use of antibiotics over the last 6 months;~ * Ongoing drug therapy that might have an impact on the clinical signs and symptoms of periodontitis;~ * Pregnancy or nursing;~ * Current and former smokers.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- SRP + Injectable Platelet-Rich Fibrin (Type: EXPERIMENTAL): Scaling and root planing in conjunction with Injectable Platelet-Rich Fibrin
- SRP + placebo (Type: PLACEBO_COMPARATOR): Scaling and root planing in conjunction with saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Prophylactic Ibuprofen Versus Placebo on Pain Relief and Success Rates of Medical Abortion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Good general health~* Pregnancy of up to 7 weeks gestation.~* Approval from the Ministry of Health committee for termination of pregnancy after an intrauterine pregnancy was demonstrated by an ultrasound exam.~* Subjects that provided informed consent and agree to comply with all study procedures.~Exclusion Criteria:~* Known allergy to mifepristone, misoprostol, paracetamol or NSAIDs.~* Severe anemia.~* Drug or alcohol abuse~* Known abnormal liver function (liver function tests greater than 1.5 times upper range of normal).~* Known abnormal renal function (serum creatinine \> 1.5 mg/dl).~* Abnormal blood tests~* Exclusionary health problems contraindicating mifepristone included adrenal disease; sickle cell anemia; severe liver, respiratory, or renal disease; and blood clotting defect.~* Chronic disease~* Patient is participating currently in another clinical trial

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- ibuprofen (Type: EXPERIMENTAL): the group will receive 2 tablets of ibuprofen 400 mg at the time of misoprostol administration. The information about the effect of the analgesics on the pain, and on the course of medical abortion, will be prospectively gathered from questionnaires completed by the study participants
- placebo (Type: NO_INTERVENTION): this group will receive 2 placebo tablets together with the misoprostol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 9 years of age.~* Primary, axillary hyperhidrosis of at least 6 months duration.~* Hyperhidrosis Disease Severity Scale (HDSS) of 3 or 4 at Baseline.~* Axillary Sweating Daily Diary (ASDD) ≥ 4 at Baseline.~* Sweat production of at least 50 mg over 5 minutes in each axilla assessed gravimetrically.~Exclusion Criteria:~* Prior surgical procedure for hyperhidrosis.~* Prior axillary treatment with an anti-hyperhidrosis medical device (approved or investigational).~* Prior treatment with botulinum toxin (e.g., Botox®) for axillary hyperhidrosis within 1 year of Baseline/Day 1.~* Previous active treatment in the Dermira DRM04-HH01 or DRM04-HH02 clinical trials.~* Axillary use of nonprescription antiperspirants within 1 week or prescription antiperspirants within 2 weeks of Baseline.~* Subjects on new or regimens of psychotherapeutic medications that have changed within 2 months of baseline.~* Treatment with systemic anticholinergics within 4 weeks of the baseline visit unless dosing has been stable for at least 4 months.~* Other treatment with glycopyrrolate within 4 weeks prior to Baseline.~* Secondary axillary hyperhidrosis or presence of a condition that may cause secondary hyperhidrosis.~* History of Sjögren's syndrome or Sicca syndrome.~* History of glaucoma, inflammatory bowel disease, toxic megacolon, or febrile illness.~* Men with a history of urinary retention requiring catheterization due to prostatic hypertrophy or severe obstructive symptoms of prostatic hypertrophy.~* History or presence of ventricular arrhythmias, atrial fibrillation, atrial flutter.~* Other systemic diseases or active uncontrolled infections, or any other condition which, in the judgment of the Investigator, would put the subject at unacceptable risk for participation in the study.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- glycopyrronium (Type: EXPERIMENTAL): glycopyrronium Topical Wipes
- Vehicle (Type: PLACEBO_COMPARATOR): glycopyrronium Topical Wipes, Vehicle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Research Study Efficacy of a Prototype Oral Rinse

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female volunteers 18-65 years of age~2. Good general health~3. Must sign informed consent form~4. Minimum of 16 natural uncrowned teeth (excluding third molars) must be present.~5. No history of allergy to personal care consumer products, or their ingredients, relevant to any ingredient in the test products as determined by the dental/medical professional monitoring the study.~6. Dental Selection Criteria: Gingivitis patients with a minimum of 16 gradable teeth with a minimum of 6 sites with a GI score of ≥ 3. Subjects will be stratified according to gingivitis severity. Average full mouth GI score should be in the range of 2.0 - 2.5. heavy plaque formers should be avoided. Target a full mouth PI (Quigley-Hein) to be in the range of 1.5-3.0~Exclusion Criteria:~1. Subjects unable or unwilling to sign the informed consent form.~2. Medical condition which requires pre-medication prior to dental visits/procedures~3. Moderate or advanced periodontal disease~4. History of allergy to iodine~5. History of thyroid disease~6. History of diabetes~7. 2 or more decayed untreated dental sites at screening.~8. Other disease of the hard or soft oral tissues.~9. Impaired salivary function (e.g. Sjogren's syndrome or head and neck irradiation).~10. Use of medications that are currently affect salivary flow.~11. Use of antibiotics or antimicrobial drugs within 30 days prior to study visit #1.~12. Pregnant or nursing women.~13. Participation in any other clinical study within 1 week prior to enrollment into this study.~14. Use of tobacco products~15. Subjects who must receive dental treatment during the study dates.~16. Current use of Antibiotics for any purpose.~17. Presence of an orthodontic appliance.~18. History of allergy to common dentifrice ingredients~19. Immune compromised individuals (HIV, AIDS, immuno suppressive drug therapy)~20. Women of childbearing potential and not on birth control (Diaphragm, birth control pills or implants, IUD (Intrauterine device), condoms).~21. Smoker

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: PLACEBO_COMPARATOR): control mouthrinse
- B (Type: EXPERIMENTAL): new prototype mouthrinse

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of Regorafenib

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with mCRC who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom the decision has been made per investigator's routine treatment practice to prescribe regorafenib.~Exclusion Criteria:~* Patients participating in an investigational program with interventions outside of routine clinical practice

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of acne vulgaris~* Willing to avoid excessive or prolonged exposure to ultraviolet light (eg, sunlight, tanning beds) throughout the study~Exclusion Criteria:~* Severe cystic acne, acne conglobata, acne fulminans, or secondary acne~* Use of phototherapy devices (eg, ClearLight™), energy-based devices, adhesive cleansing strips (eg, Pond's®, Biore®), or cosmetic procedures (eg, facials, peeling, comedo extraction) in the past week~* Use of anti-inflammatory medications, salicylic acid; corticosteroids, antibiotics, antibacterials (including benzoyl peroxide-containing products \[eg, benzamycin\]), retinoids; other topical acne treatments (eg, photodynamic therapy, medicated soaps such as those containing benzoyl peroxide, salicylic acid, sulfur, or sodium sulfacetamide) in the past 2 weeks~* Use of birth control pills strictly for acne control

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dapsone Gel (Type: EXPERIMENTAL): Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
- Dapsone Gel Vehicle (Type: PLACEBO_COMPARATOR): Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Colchicine to Treat and Prevent Recurrent Pericarditis (First Episode)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with the first attack of recurrent pericarditis~* Age≥ 18 years~* Informed consent~Exclusion Criteria:~* Suspected neoplastic, tuberculous, or purulent etiology~* Known severe liver disease and/or elevated transaminases \>1.5 times the upper limit of normality~* Serum creatinine \>2.5 mg/dl~* Serum creatine kinase (CK) over the upper limit of normality or known myopathy~* Known gastrointestinal or blood disease~* Pregnant or lactating women or women not protected by a contraception method~* Known hypersensibility to colchicine~* Treatment with colchicine at enrolment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Comparator
- Colchicine (Type: EXPERIMENTAL): Colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 6 month in patients ≥70 kg, and halved doses for patients \<70 kg or intolerant to the highest dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete